Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068755 | 0.88 | DYRK1A (1.00) | DYRK1ACLK1CLK2DYRK2CLK4 | |
| SCHEMBL20068760 | 0.88 | DYRK1A (1.00) | DYRK1A | |
| SCHEMBL20068756 | 0.87 | DYRK1A (0.77) | DYRK1ACLK1CLK2DYRK2CLK4 | |
| SCHEMBL20068738 | 0.85 | DYRK1A (0.75) | DYRK1ACLK1CLK2DYRK2CLK4 | |
| SCHEMBL23015694 | 0.83 | DYRK1A (1.00) | DYRK1A | |
| SCHEMBL20068763 | 0.83 | DYRK1A (1.00) | DYRK1ACLK1CLK2DYRK2CLK4 | |
| SCHEMBL20068759 | 0.83 | DYRK1A (1.00) | DYRK1ACLK1CLK2DYRK2CLK4 | |
| SCHEMBL20068762 | 0.80 | DYRK1A (1.00) | DYRK1A | |
| SCHEMBL30416554 | 0.80 | DYRK1A (1.00) | DYRK1A | |
| SCHEMBL20069184 | 0.76 | DYRK1A (1.00) | DYRK1ACLK1CLK2DYRK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526216-B1 | BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS | PHARMASUM THERAPEUTICS AS (NO) | 2024-04-03 | — | — | EP | disclosed |
| CN-109843879-B | Benzothiazole derivatives as DYRK1 inhibitors | 药物治疗股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | PHARMASUM THERAPEUTICS AS (NO) | 2021-02-23 | — | — | US | disclosed |
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | PHARMASUM THERAPEUTICS AS (NO) | 2021-02-23 | — | — | US | disclosed |
| WO-2018069468-A1 | BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS | PHARMASUM THERAPEUTICS AS (NO) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | DYRK1A, DYRK1B, PDK2 | DYRK1A 1/4885CLK1 86/4885CLK2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.